- Home
- ADTX vs NCNA Comparison
ADTX vs NCNA Comparison
Compare ADTX & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADTX
- NCNA
- Stock Information
- Founded
- ADTX 2017
- NCNA 1997
- Country
- ADTX United States
- NCNA United Kingdom
- Employees
- ADTX N/A
- NCNA N/A
- Industry
- ADTX Biotechnology: Pharmaceutical Preparations
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- ADTX Health Care
- NCNA Health Care
- Exchange
- ADTX Nasdaq
- NCNA Nasdaq
- Market Cap
- ADTX 5.3M
- NCNA 4.5M
- IPO Year
- ADTX 2020
- NCNA 2017
- Fundamental
- Price
- ADTX $2.30
- NCNA $0.55
- Analyst Decision
- ADTX
- NCNA Buy
- Analyst Count
- ADTX 0
- NCNA 2
- Target Price
- ADTX N/A
- NCNA $25.00
- AVG Volume (30 Days)
- ADTX 589.6K
- NCNA 143.6K
- Earning Date
- ADTX 05-19-2025
- NCNA 05-15-2025
- Dividend Yield
- ADTX N/A
- NCNA N/A
- EPS Growth
- ADTX N/A
- NCNA N/A
- EPS
- ADTX N/A
- NCNA N/A
- Revenue
- ADTX $133,985.00
- NCNA N/A
- Revenue This Year
- ADTX $15,768.94
- NCNA N/A
- Revenue Next Year
- ADTX N/A
- NCNA N/A
- P/E Ratio
- ADTX N/A
- NCNA N/A
- Revenue Growth
- ADTX N/A
- NCNA N/A
- 52 Week Low
- ADTX $2.04
- NCNA $0.69
- 52 Week High
- ADTX $27,200.00
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- ADTX 30.46
- NCNA 35.90
- Support Level
- ADTX $2.21
- NCNA $0.71
- Resistance Level
- ADTX $2.39
- NCNA $0.89
- Average True Range (ATR)
- ADTX 0.39
- NCNA 0.09
- MACD
- ADTX 0.49
- NCNA -0.02
- Stochastic Oscillator
- ADTX 11.11
- NCNA 0.00
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.